Elevai Labs, Inc. is a public company focused on advancing health technology through innovative artificial intelligence solutions
The company specializes in developing AI-driven platforms that enhance medical diagnostics, treatment planning, and patient care. By leveraging machine learning algorithms and data analysis, Elevai Labs aims to improve the accuracy and efficiency of healthcare delivery, ultimately transforming the way medical professionals make decisions and interact with patients. Their commitment to research and development positions them at the forefront of a rapidly evolving sector, addressing critical challenges in healthcare with cutting-edge technology.
NEWPORT BEACH, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. ("Northstrive"), a subsidiary of PMGC Holdings Inc. (NASDAQELAB) ("PMGC," "we," or "our"), announced an update for its innovative obesity treatment candidates, EL-22 and EL-32, both aimed at optimizing fat loss while preserving muscle mass in patients undergoing weight loss therapies, including GLP-1 receptor agonists.
NEWPORT BEACH, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the “Company” or “PMGC”) (Nasdaq: ELAB) is pleased to announce that its operating investment division, PMGC Capital LLC, has begun building its portfolio with strategic investments in the fire prevention technology and the U.S. uranium energy market. These initial investments underscore the Company's commitment to financing innovation in essential industries with significant growth opportunities.
NEWPORT BEACH, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB), today announced that its subsidiary, Northstrive Biosciences Inc. (“Northstrive Biosciences”), has executed a research agreement (“Research Agreement”) with a leading preclinical contract research organization (“CRO”) specializing in metabolic disorders. This Research Agreement will support a preclinical study carried out by the CRO and designed to evaluate EL-32, a novel engineered probiotic, as a monotherapy and in combination with the GLP-1 receptor agonist semaglutide, focusing on its impact on glycemic control and body composition in diet-induced obese (DIO) mice. Pursuant to the research agreement, within three months of completion of this study, the CRO will provide results of this study to Northstrive Biosciences and deliver a report to Northstrive Biosciences describing the work envisaged in the Research Agreement.
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
NEWPORT BEACH, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB) a diversified holding company today announced it has entered into a warrant inducement agreement with existing institutional investors for the exercise of certain outstanding Series A warrants that the Company issued on September 24, 2024. Pursuant to the warrant inducement agreement, the investors have agreed to exercise the outstanding warrants to purchase an aggregate of 969,385 shares of the Company's common stock at an amended exercise price of $2.00. The gross proceeds from the exercise of the warrants are expected to be approximately $1.9 million, prior to deducting placement agent fees and estimated offering expenses.
Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
PMGC Holdings Inc. (NASDAQELAB) shares are trading higher Friday after the company announced that its subsidiary, Northstrive Biosciences, will present at an upcoming UCLA symposium on anti-obesity treatments.
Northstrive Biosciences Inc. was invited to present EL-22, a novel myostatin asset aimed at preserving muscle while on weight loss treatments, at the UCLA Obesity Symposium called Anti-Obesity Treatments: Challenges and Emerging Solutions, organized by UCLA Metabolism Theme. This is an invite only event that brings together industry leading voices in the obesity space.
NEWPORT BEACH, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB) is pleased to announce the renaming of its wholly owned subsidiaries as part of a strategic effort to better align with the company's evolving business focus as a diversified holding company. Effective immediately, the following name changes have taken place:
NEWPORT BEACH, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc (NASDAQELAB), a diversified holding company, and Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced that it entered into a definitive purchase agreement with PMGC Holdings Inc. (formerly Elevai Labs Inc.) and its wholly owned subsidiary, Elevai Skincare Inc. (“Elevai”), to acquire the assets related to its skincare and haircare business (the “Acquisition”).
NEWPORT BEACH, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly known as Elevai Labs Inc.) (Nasdaq: ELAB) (before and after the redomestication, the “Company” or “we”) announced today that it completed a strategic reorganization. This reorganization included changing the Company’s name from Elevai Labs Inc. to PMGC Holdings Inc. and redomiciling from Delaware to Nevada. Upon this reorganization, the Company will continue to trade on The Nasdaq Stock Market (“Nasdaq”) under the ticker symbol “ELAB.” The redomestication and name change will be effective on Nasdaq at the opening of business on December 23, 2024.
NEWPORT BEACH, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly known as Elevai Labs Inc.) (Nasdaq: ELAB) (before and after the redomestication, the “Company” or “we”) announced today that it plans to effectuate a strategic reorganization effective on December 20, 2024. This reorganization will include changing the Company’s name from Elevai Labs Inc. to PMGC Holdings Inc. and redomiciling from Delaware to Nevada. After this reorganization, the Company will continue to trade on The Nasdaq Stock Market (“Nasdaq”) under the ticker symbol “ELAB.” The redomestication and name change will be effective on Nasdaq at the opening of business on December 23, 2024.
NEWPORT BEACH, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (Nasdaq: ELAB) (“Elevai” or the “Company”), a diversified holding company, subsidiary Elevai Biosciences Inc. (“Elevai Biosciences”), today announced the next steps in its regulatory strategy for EL-22, aimed at treating obesity and preserving muscle mass.
